Published in Proc Natl Acad Sci U S A on December 23, 1997
GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem (2008) 4.51
Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest (2001) 2.35
An overview of the serpin superfamily. Genome Biol (2006) 2.14
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J (2006) 1.59
Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci (2000) 1.58
Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A (2002) 1.46
Monitoring of heparin and its low-molecular-weight analogs by silicon field effect. Proc Natl Acad Sci U S A (2006) 1.45
Anticoagulant heparan sulfate: structural specificity and biosynthesis. Appl Microbiol Biotechnol (2006) 1.42
Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions. Biochem Biophys Res Commun (2005) 1.29
Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s). J Med Chem (2006) 1.28
Intracellular proteoglycans. Biochem J (2004) 1.25
Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J (2001) 1.08
Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex. Proc Natl Acad Sci U S A (2009) 1.07
Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition. J Biol Chem (2005) 1.07
Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem (2006) 1.05
Structural mechanism for the carriage and release of thyroxine in the blood. Proc Natl Acad Sci U S A (2006) 1.05
Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci U S A (2003) 1.04
Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function. J Biol Chem (2009) 1.04
The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J Mol Biol (2009) 1.02
Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides. Anal Chem (2009) 1.01
Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomater (2011) 0.98
The roles of serpins in mosquito immunology and physiology. J Insect Physiol (2012) 0.98
Heparan sulfate 3-O-sulfation: a rare modification in search of a function. Matrix Biol (2013) 0.98
Proteoglycan sequence. Mol Biosyst (2012) 0.98
Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie (2010) 0.97
Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics. Future Med Chem (2012) 0.96
On designing non-saccharide, allosteric activators of antithrombin. Eur J Med Chem (2008) 0.96
The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood (2005) 0.94
Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol (2007) 0.94
X-ray crystal structure of MENT: evidence for functional loop-sheet polymers in chromatin condensation. EMBO J (2006) 0.94
Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J (2006) 0.93
Understanding Dermatan Sulfate-Heparin Cofactor II Interaction through Virtual Library Screening. ACS Med Chem Lett (2010) 0.93
Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa. J Biol Chem (2008) 0.93
Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design. J Mol Biol (2009) 0.93
Identification of heparin-binding sites in proteins by selective labeling. Mol Cell Proteomics (2009) 0.92
Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem (2008) 0.91
Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest (1999) 0.91
Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost (2009) 0.91
Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am J Pathol (1999) 0.91
Designing nonsaccharide, allosteric activators of antithrombin for accelerated inhibition of factor Xa. J Med Chem (2011) 0.90
The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J Biol Chem (2009) 0.90
Immune challenge induces N-terminal cleavage of the Drosophila serpin Necrotic. Insect Biochem Mol Biol (2005) 0.88
Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement. FEBS Lett (2009) 0.88
Structure of an engineered β-lactamase maltose binding protein fusion protein: insights into heterotropic allosteric regulation. PLoS One (2012) 0.88
On the specificity of heparin/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different. PLoS One (2012) 0.88
Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb Haemost (2014) 0.88
Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol (2013) 0.87
Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost (2013) 0.87
Allosteric modulation of hormone release from thyroxine and corticosteroid-binding globulins. J Biol Chem (2011) 0.87
Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. J Biol Chem (2014) 0.86
Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands. Biochem J (2003) 0.85
Toward a robust computational screening strategy for identifying glycosaminoglycan sequences that display high specificity for target proteins. Glycobiology (2014) 0.85
Biochemical characterization of Anopheles gambiae SRPN6, a malaria parasite invasion marker in mosquitoes. PLoS One (2012) 0.85
Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol (2006) 0.84
Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry (2008) 0.84
Crystal structure of histidine-rich glycoprotein N2 domain reveals redox activity at an interdomain disulfide bridge: implications for angiogenic regulation. Blood (2014) 0.83
Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes. Arch Biochem Biophys (2010) 0.83
Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One (2012) 0.83
Protein misfolding and the serpinopathies. Prion (2007) 0.83
Exploiting enzyme specificities in digestions of chondroitin sulfates A and C: production of well-defined hexasaccharides. Glycobiology (2012) 0.82
Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa. J Biol Chem (2010) 0.81
Fibroblast growth factor-based signaling through synthetic heparan sulfate blocks copolymers studied using high cell density three-dimensional cell printing. J Biol Chem (2014) 0.81
Glycosaminoglycans from earthworms (Eisenia andrei). Glycoconj J (2009) 0.81
Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs. Sci Rep (2016) 0.80
Capillary electrophoretic study of small, highly sulfated, non-sugar molecules interacting with antithrombin. Electrophoresis (2009) 0.80
Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin. J Biol Chem (2008) 0.80
A Simple Method for Discovering Druggable, Specific Glycosaminoglycan-Protein Systems. Elucidation of Key Principles from Heparin/Heparan Sulfate-Binding Proteins. PLoS One (2015) 0.80
Peptidomic Analysis of Rat Plasma: Proteolysis in Hemorrhagic Shock. Shock (2016) 0.80
Crystal structure of native Anopheles gambiae serpin-2, a negative regulator of melanization in mosquitoes. Proteins (2011) 0.79
Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III. Biochem J (2002) 0.79
Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin. Biochemistry (2006) 0.79
De novo design of self-assembling foldamers that inhibit heparin-protein interactions. ACS Chem Biol (2014) 0.79
Designing "high-affinity, high-specificity" glycosaminoglycan sequences through computerized modeling. Methods Mol Biol (2015) 0.79
Investigating changes in the gas-phase conformation of Antithrombin III upon binding of Arixtra using traveling wave ion mobility spectrometry (TWIMS). Analyst (2015) 0.79
Antithrombin-binding oligosaccharides: structural diversities in a unique function? Glycoconj J (2014) 0.78
Three-dimensional structural aspects of protein-polysaccharide interactions. Int J Mol Sci (2014) 0.78
Community-based network study of protein-carbohydrate interactions in plant lectins using glycan array data. PLoS One (2014) 0.78
How does heparin prevent the pH inactivation of cathepsin B? Allosteric mechanism elucidated by docking and molecular dynamics. BMC Genomics (2010) 0.78
Conformational change in the chromatin remodelling protein MENT. PLoS One (2009) 0.78
Chemoenzymatic synthesis and structural characterization of 2-O-sulfated glucuronic acid-containing heparan sulfate hexasaccharides. Glycobiology (2014) 0.78
Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Biochem J (2016) 0.78
Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition. J Nat Sci Biol Med (2014) 0.76
Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin. Thromb Haemost (2014) 0.76
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex. J Biochem (2012) 0.76
Three-dimensional structure of a schistosome serpin revealing an unusual configuration of the helical subdomain. Acta Crystallogr D Biol Crystallogr (2012) 0.76
Serpins in arthropod biology. Semin Cell Dev Biol (2016) 0.76
Structural and inhibitory effects of hinge loop mutagenesis in serpin-2 from the malaria vector Anopheles gambiae. J Biol Chem (2014) 0.76
Polysulfated trehalose as a novel anticoagulant agent with dual mode of action. Biomed Res Int (2015) 0.75
Hedgehogs like it sweet, too. Proc Natl Acad Sci U S A (2006) 0.75
Replacement of Phe274 with conserved residue Tyr274 for reactive center loop expulsion in antithrombin. Clin Appl Thromb Hemost (2010) 0.75
Crystallization and crystallographic studies of kallistatin. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Mechanistic and therapeutic overview of glycosaminoglycans: the unsung heroes of biomolecular signaling. Glycoconj J (2015) 0.75
Uncovering the Relationship between Sulphation Patterns and Conformation of Iduronic Acid in Heparan Sulphate. Sci Rep (2016) 0.75
Role of P2 glycine in determining the specificity of antithrombin reaction with coagulation proteases. Biochem Biophys Res Commun (2009) 0.75
Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions. Chem Sci (2015) 0.75
All-Atom Internal Coordinate Mechanics (ICM) Force Field for Hexopyranoses and Glycoproteins. J Chem Theory Comput (2015) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol (1984) 3.60
Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry (1989) 3.18
Biological implications of a 3 A structure of dimeric antithrombin. Structure (1994) 2.78
Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem (1992) 2.24
Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res (1982) 1.83
Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol (1996) 1.66
The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol (1994) 1.63
Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun (1983) 1.62
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J (1984) 1.49
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Mobile reactive centre of serpins and the control of thrombosis. Nature (1991) 1.36
Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry (1996) 1.35
The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol (1997) 1.27
Structural basis for serpin inhibitor activity. Proteins (1995) 1.20
Crystal structure of cleaved bovine antithrombin III at 3.2 A resolution. J Mol Biol (1993) 1.08
A mechanism for heparin-induced potentiation of antithrombin III. Nat Struct Biol (1994) 1.07
Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem (1997) 1.00
Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. J Biol Chem (1996) 0.99
Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol (1997) 0.96
Transmission of conformational change from the heparin binding site to the reactive center of antithrombin. Biochemistry (1993) 0.94
Specific modification of the functional arginine residue in soybean trypsin inhibitor (Kunitz) by peptidylarginine deiminase. J Biol Chem (1985) 0.93
Targeting the glycosaminoglycan-binding sites on proteins. Chem Biol (1994) 0.93
Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. J Biol Chem (1989) 0.92
Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A beta-sheet of the inhibitor during trapping of target proteinases. Biochemistry (1993) 0.91
Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity. FEBS Lett (1988) 0.91
Requirement of lysine residues outside of the proposed pentasaccharide binding region for high affinity heparin binding and activation of human antithrombin III. J Biol Chem (1996) 0.89
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser. J Clin Invest (1988) 0.88
Antithrombin and heparin. Mol Med Today (1995) 0.83
The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord (2001) 14.30
The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature (1992) 5.71
The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 4.81
Structure and variation of human alpha 1-antitrypsin. Nature (1982) 4.13
Structure of a serpin-protease complex shows inhibition by deformation. Nature (2000) 4.02
Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res (2000) 3.55
Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry (1989) 3.18
Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J Biol Chem (1983) 3.11
The estimation of red cell superoxide dismutase activity. J Lab Clin Med (1975) 2.75
Matrix methods for solving protein substructures of chlorine and sulfur from anomalous data. Acta Crystallogr D Biol Crystallogr (2001) 2.60
Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med (1983) 2.36
What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol (1995) 2.30
T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Transplantation (2000) 2.15
Variations in the structure of human haemoglobin. With particular reference to the unstable haemoglobins. Br Med Bull (1969) 2.07
Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet (1985) 1.99
Molecular cloning and structural characterization of the Arg-gingipain proteinase of Porphyromonas gingivalis. Biosynthesis as a proteinase-adhesin polyprotein. J Biol Chem (1995) 1.98
Five pseudoknots are present at the 204 nucleotides long 3' noncoding region of tobacco mosaic virus RNA. Nucleic Acids Res (1985) 1.94
Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry (1985) 1.89
Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88
A simple method for the detection of unstable haemoglobins. Br J Haematol (1972) 1.87
Clinical studies in benign (Becker type) X-linked muscular dystrophy. Clin Genet (1976) 1.79
Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood (2001) 1.77
Reactions involving superoxide and normal and unstable haemoglobins. Biochem J (1976) 1.66
Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci (1988) 1.66
Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol (1996) 1.66
The crystal structure of the nucleotide-free alpha 3 beta 3 subcomplex of F1-ATPase from the thermophilic Bacillus PS3 is a symmetric trimer. Structure (1997) 1.65
Feasibility of neonatal screening for Duchenne muscular dystrophy. J Med Genet (1982) 1.62
Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun (1983) 1.62
alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest (1986) 1.61
Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway. J Clin Invest (1994) 1.56
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer (1996) 1.54
Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci U S A (2000) 1.54
The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. Proc Natl Acad Sci U S A (1996) 1.54
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res (1990) 1.53
A circulating variant of human proalbumin. Nature (1978) 1.52
Crystal structure of uncleaved ovalbumin at 1.95 A resolution. J Mol Biol (1991) 1.52
Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry (1993) 1.49
Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47
Prospective study of genetic counselling. Br Med J (1979) 1.47
Abnormal haem binding and globin SH group blockade in unstable haemoglobins. Nature (1968) 1.44
Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature (1985) 1.44
Molecular cloning and characterization of Porphyromonas gingivalis lysine-specific gingipain. A new member of an emerging family of pathogenic bacterial cysteine proteinases. J Biol Chem (1997) 1.43
Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature (1990) 1.42
Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem (1993) 1.41
Activated oxygen and haemolysis. Br J Haematol (1975) 1.41
A new hemoglobin variant resembling hemoglobin E. Hemoglobin E Saskatoon: beta-22 Glu replaced by Lys. Can J Biochem (1967) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J (1981) 1.39
Studies of hemoglobin denaturation and Heinz body formation in the unstable hemoglobins. J Clin Invest (1974) 1.39
Arginine-specific protease from Porphyromonas gingivalis activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. Infect Immun (2001) 1.35
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem (1998) 1.34
Imprisonment of J-P Allain. Lancet (1993) 1.34
Haemoglobin Köln (beta-98 valine--methionine): an unstable protein causing inclusion-body anaemia. Nature (1966) 1.33
Analysis of expressed sequence tag loci on wheat chromosome group 4. Genetics (2004) 1.33
alpha 1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization. J Biol Chem (1995) 1.33
Differences between alpha- and beta-chain mutants of human haemoglobin and between alpha- and beta-thalassaemia. Possible duplication of the alpha-chain gene. Br Med J (1968) 1.33
A study of possible heterogeneity in Duchenne muscular dystrophy. Clin Genet (1979) 1.31
Effects of mutations in the hinge region of serpins. Biochemistry (1993) 1.29
The unstable haemoglobin haemolytic anaemias. Semin Hematol (1969) 1.27
The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol (1997) 1.27
Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol (1998) 1.26
A 2.6 A structure of a serpin polymer and implications for conformational disease. J Mol Biol (1999) 1.26
Structural and functional characterization of the abnormal Z alpha 1-antitrypsin isolated from human liver. FEBS Lett (1984) 1.24
Linkage between the loci for benign (Becker-type) X-borne muscular dystrophy and deutan colour blindness. J Med Genet (1974) 1.24
Oxidation of human haemoglobin by copper. Mechanism and suggested role of the thiol group of residue beta-93. Biochem J (1977) 1.22
The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem (2001) 1.22
The detection of carriers of benign (Becker-type) X-linked muscular dystrophy. J Med Genet (1975) 1.21
Controversial glycosaminoglycan conformations. Nature (1986) 1.20
Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry (1987) 1.18
Cleaved antitrypsin polymers at atomic resolution. Protein Sci (2000) 1.17
Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis. Infect Immun (1995) 1.17
Hirschsprung's disease and congenital deafness. J Med Genet (1973) 1.17
Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Lett (1998) 1.16
The significance of monoclonal gammopathy in a normal population. Aust N Z J Med (1971) 1.16
Basis of the defect in alpha-1-antitrypsin deficiency. Nature (1973) 1.16
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol (1986) 1.15
Synthesis of conformationally locked L-iduronic acid derivatives: direct evidence for a critical role of the skew-boat 2S0 conformer in the activation of antithrombin by heparin. Chemistry (2001) 1.15
Preparation and characterization of latent alpha 1-antitrypsin. J Biol Chem (1995) 1.15
Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest (1994) 1.14
Crystallization of F1-ATPase from bovine heart mitochondria. J Mol Biol (1993) 1.14
Prevalence of antithrombin deficiency in the healthy population. Br J Haematol (1994) 1.13
Yeast KEX2 protease has the properties of a human proalbumin converting enzyme. Science (1987) 1.13
Effect of free and vesicle-bound cysteine proteinases of Porphyromonas gingivalis on plasma clot formation: implications for bleeding tendency at periodontitis sites. Infect Immun (1995) 1.13
An atlas of serpin conformations. Trends Biochem Sci (1998) 1.13
A new doubly substituted sickling haemoglobin: HbS-Oman. Br J Haematol (1989) 1.12
Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin. J Mol Biol (2000) 1.12
The amino acid sequence of the alpha chain of the major haemoglobin of the rat (Rattus norvegicus). Biochem J (1975) 1.11
Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta (1985) 1.11
Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest (1995) 1.10
Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge. J Biol Chem (1989) 1.10
alpha 1-Antitrypsin microheterogeneity. Isolation and physiological significance of isoforms. Biochim Biophys Acta (1982) 1.10
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun (1985) 1.09
Structural characterization of sulfated glycosaminoglycans by fast atom bombardment mass spectrometry: application to heparin fragments prepared by chemical synthesis. Carbohydr Res (1987) 1.08
Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J (2001) 1.08
Crystal structure of cleaved bovine antithrombin III at 3.2 A resolution. J Mol Biol (1993) 1.08